Detection of hepatocellular cancer during screening of 1125 patients with chronic hepatitis virus infection

Izzo, F.; Cremona, Francesco; Ruffolo, F.; Palaia, Raffaéle; Parisi, Valerio; Curley, Steven A.

doi:10.1179/joc.1997.9.2.151

Cited by 8 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the evidence-based data for HCC surveillance is low to moderate, including only two randomized trials in patients with chronic hepatitis B infection (HBV) with a significant risk of bias [ 11 , 12 ] and several observational studies in cirrhosis [ 13 , 14 , 15 , 16 ], surveillance for HCC is broadly recommended by international guidelines [ 17 ]. This recommendation is supported by several epidemiological reasons.…”

Section: Biomarkers For Hepatocellular Carcinoma Surveillance and mentioning

confidence: 99%

“…It should be noted that the evidence regarding HCC surveillance is moderate in chronic HBV and weak in patients with cirrhosis [ 11 , 12 , 13 , 14 , 15 , 16 ]. No randomized controlled trials assessing the survival benefit of HCC surveillance in patients with cirrhosis were reported, and in some studies, factors such as lead-time bias (apparent improvement in survival derived from early diagnosis) were not appropriately considered [ 20 ].…”

Section: Biomarkers For Hepatocellular Carcinoma Surveillance and mentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment

Piñero

Dirchwolf

Pessôa

2020

Cells

332

255

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and treatment strategies to improve the prognosis of this malignancy. The identification of useful biomarkers for surveillance and early HCC diagnosis is still deficient, with available serum biomarkers showing low sensitivity and heterogeneous specificity despite different cut-off points, even when assessed longitudinally, or with a combination of serum biomarkers. In contrast, HCC biomarkers used for prognostic (when associated with clinical outcomes) or predictive purposes (when associated with treatment response) may have an increased clinical role in the near future. Furthermore, some serum biomarkers are already implicated as a treatment selection tool, whether to provide access to certain therapies or to assess clinical benefit after treatment. In the present review we will discuss the clinical utility and foreseen future of HCC biomarkers implicated in surveillance, diagnosis, prognosis, and post-treatment assessment.

show abstract

Section: Biomarkers For Hepatocellular Carcinoma Surveillance and mentioning

confidence: 99%

Section: Biomarkers For Hepatocellular Carcinoma Surveillance and mentioning

confidence: 99%

Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment

Piñero

Dirchwolf

Pessôa

2020

Cells

332

255

View full text Add to dashboard Cite

show abstract

“…143 This finding accords well with several other studies which suggest that patients who receive supportive care alone have a median survival in the range 3-7 months. 83,137,[144][145][146] However, these figures are likely to be affected by selection bias. For example, patients may be more likely to receive no active treatment if they present with the kind of advanced, symptomatic tumour that places them at the gloomier end of the prognostic spectrum.…”

Section: Natural Historymentioning

confidence: 99%

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

151

108

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: K Stein received an unrestricted grant from Schering Plough (UK) to carry out work on the cost-effectiveness of combination therapy for hepatitis C in 2000. KS is also a member of the editorial board for Health Technology Assessment, but he was not involved in the editorial process for this report. M Cramp sits on hepatitis C advisory boards for Schering Plough, Gilead and Roche. He has received unrestricted educational grants from Roche and Schering Plough to support research and service development. He has been awarded an NHS R&D grant looking at injecting drug users who do not have hepatitis C virus infection. J Thompson Coon received a grant from the Hepatitis C Trust to conduct a systematic review of complementary and alternative therapies for the treatment of chronic hepatitis C. HTA Published September 2007This report should be referenced as follows: NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, man...

show abstract

“…A large cohort study 4 carried out in Italy showed a significant presence of HCC among patients affected by viral hepatitis. Specifically, HCV-related liver cirrhosis accounts for about 4% risk per year of developing HCC [5][6] , and the tumor incidence in North America, Europe and Japan is increasing, mainly as a consequence of HCV diffusion during the previous decades 1 .…”

Section: Introductionmentioning

confidence: 99%

“…Although the mechanisms by which the virus promotes hepatocarcinogenesis are not completely clear yet, interferon (IFN) therapy seems of benefit in preventing HCC, owing to antimitogenic and antioxidative properties, both in sustained virological responders and in transient biochemical responders [7][8][9] . Since tumor diffusion significantly limits an effective removal of lesions 4 , procedures for disclosing primary nodules in cirrhotics have been carefully standardized by major scientific societies 10 . Nevertheless, early diagnosis of HCC is often arduous in clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Occurrence of Diffuse, Poorly Differentiated Hepatocellular Carcinoma During Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C

Capanni

Lorefice²,

Benini³

et al. 2008

Journal of Chemotherapy

View full text Add to dashboard Cite

SummaryInterferon therapy is indicated for the treatment of chronic hepatitis C and prevention of hepatocellular carcinoma. We describe the case of a 66-year-old Italian woman who received pegylated interferon α α-2a plus ribavirin combined therapy for HCV-related chronic liver disease. Preliminary hematochemical, ultrasound and bioptic investigations did not show liver cirrhosis or hepatocarcinoma. After 24 weeks of treatment transaminase serum levels were in the normal range and circulating HCV-RNA was undetectable by PCR qualitative assay. On week 46 a serious adverse event occurred, with rapid transaminase increase, severe hyperpyrexia, and abdominal pain, leading to interruption of interferon and ribavirin. Liver biopsy was repeated and it revealed poorly differentiated hepatocellular carcinoma. Only palliative care could be performed and the patient died of liver failure within 2 months. The present case underlines that hepatocellular carcinoma can be misdiagnosed in spite of laboratory and instrumental follow-up. More sensitive tools are needed for tumor detection, to avoid IFN impairment of the liver, even though it eradicates HCV.

show abstract

Detection of hepatocellular cancer during screening of 1125 patients with chronic hepatitis virus infection

Cited by 8 publications

References 2 publications

Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment

Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Occurrence of Diffuse, Poorly Differentiated Hepatocellular Carcinoma During Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C

Contact Info

Product

Resources

About